Abstract
The sensitivity of 12Pseudomonas aeruginosa strains (5 mucoid and 7 non-mucoid strains) to serum and the interaction of these strains with the complement system was studied. Five strains (4 mucoid and 1 non-mucoid strains) were lysed in 20 % normal serum as measured by the release of rediolabelled material from3H-adenine labelled bacteria. Three of these strains were also lysed in MgEGTA chelated serum. All strains activated complement via the classical pathway, and six strains were able to activate the alternative complement pathway as well. Slime production did not interfere with bacteriolysis and complement consumption.
Keywords
Internal Medicine Normal Serum Complement System Classical Pathway Complement Pathway
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Peterson, P. K.: Host defense againstPseudomonas aeruginosa. In: Sabath, L. D. (ed.):Pseudomonas aeruginosa, the organism, diseases, it causes and their treatment. Hans Hubert Publishers, Bern, 1980, p. 103–118.Google Scholar
- 2.Bodey, G. P., Buckley, M., Sathe, Y. S., Freireich, E. J.: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966, 64: 238–340.Google Scholar
- 3.Pennington, J. E.: Lipopolysaccharide Pseudomonas vaccine: efficacy against pulmonary infection withPseudomonas aeruginosa. Journal of Infectious Diseases 1979, 140: 73–80.PubMedGoogle Scholar
- 4.Tapper, M. L., Armstrong, D.: Bacteremia due toPseudomonas aeruginosa complicating neoplastic diseases: a progress report. Journal of Infectious Diseases 1974. 133: Supplement 14–23.Google Scholar
- 5.Valdivieso, M., Gil-Extremera, B., Zormoza, J., Rodriguez, V., Bodey, G. P.: Gram-negative bacillary pneumonia in the compromised host. Medicine 1977, 56: 241–254.PubMedGoogle Scholar
- 6.Whitecar, J. P., Luna, M., Bodey, G. P.: Pseudomonas bacteremia in patients with malignant disease. American Journal of the Medical Sciences 1970, 260: 216–223.Google Scholar
- 7.Winkelstein, J. A., Drachman, R. H.: Phagocytosis: the normal process and its clinically significant abnormalities. Pediatric Clinics of North America 1974, 21: 551–569.PubMedGoogle Scholar
- 8.Young, L. S., Martin, W. J., Meyer, R. D., Wein-stein, R. J., Anderson, E. T.: Gram-negative rod bacteremia: microbiologic immunologic and therapeutic considerations. Annals of Internal Medicine 1977, 86: 456–471.PubMedGoogle Scholar
- 9.Zinner, S. H., McCable, W. R.: The effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. Journal of Infectious Diseases 1976, 133: 37–45.PubMedGoogle Scholar
- 10.Young, L. S., Armstrong, D.: Human immunity toPseudomonas aeruginosa I. In vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. Journal of Infectious Diseases 1972, 126: 257–276.PubMedGoogle Scholar
- 11.Ziegler, E. J., Douglas, H.:Pseudomonas aeruginosa vasculitis and bacteremia following conjunctivitis: a simple model of fatal pseudomonal infection in neutropenia. Journal of Infectious Diseases 1979, 139: 288–296.PubMedGoogle Scholar
- 12.Sokol, P. A., Ohman, D. E., Iglewski, B. H.: A more sensitive plate assay for detection of protease production ofPseudomonas aeruginosa. Journal of Clinical Microbiology 1979, 9: 538–540.PubMedGoogle Scholar
- 13.Habs, I.: Untersuchungen über die O-Antigenie vonPseudomonas aeruginosa. Zeitschrift für Hygiene und Infektionskrankheiten 1957, 144: 218–228.Google Scholar
- 14.Forsgren, A., Quie, P. G.: Opsonic activity in human serum chelated with ethylene glycoltetraacetic acid. Immunology 1974, 26: 1251–1256.PubMedGoogle Scholar
- 15.Friedlander, A. M.: DNA release as a direct measure of microbial killing. I. Serum bactericidal activity. Journal of Immunology 1975, 115: 1401–1408.Google Scholar
- 16.Mayer, M. M.: Complement fixation. In: Kabat, E. A., Mayer, M. M. (ed.): Experimental immunochemistry. Charles C. Thomas, Springfield, 1967, p. 133–149.Google Scholar
- 17.Govan, J., Reiss-Levy, E., Bader, L., Schonell, M.:Pseudomonas pneumonia with bacteremia. Medical Journal of Australia 1977, 1: 627–628.PubMedGoogle Scholar
- 18.Vosti, K. L., Randall, E.: Sensitivity of serologically classified strains ofEscherichia coli of human origin to the serum bactericidal system. American Journal of the Medical Sciences 1970, 259: 114–119.PubMedGoogle Scholar
- 19.Guttman, R. M., Waisbren, B. A.: Bacterial blocking activity of specific IgG in chronicPseudomonas aeruginosa infection. Clinical Experimental Immunology 1975, 19: 121–130.Google Scholar
- 20.Schwarzmann, S., Boring, J. R.: Antiphagocytic effect of slime from a mucoid strain ofPseudomonas aeruginosa. Infection and Immunity 1971, 3: 762–767.Google Scholar
- 21.Høiby, N., Olling, S.:Pseudomonas aeruginosa infection in cystic fibrosis. Acta Pathologica et Microbiologica Scandinavica (C) 1977, 85: 107–114.Google Scholar
- 22.Baltimore, R. S., Mitchell, M.: Immunologic investigations of mucoid strains ofPseudomonas aeruginosa; comparison of susceptibility to opsonic antibody in mucoid and non-mucoid strains. Journal of Infectious Diseases 1975, 141: 238–247.Google Scholar
- 23.Peterson, P. K., Kim, Y., Schmeling, S., Lindeman, M., Verhoef, J., Quie, P. G.: Complementmediated phagocytosis ofPseudomonas aeruginosa. Journal of Laboratory and Clinical Medicine 1978, 92: 883–894.PubMedGoogle Scholar
Copyright information
© Vieweg Publishing 1982